Manchester Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Manchester Capital Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.85K	Hold	9	–	–	﹤0.01%	985
2026 Q1	$1.8K	Hold	9	–	–	﹤0.01%	1037
2025 Q4	$1.7K	Buy	+9	New	+$1.73K	﹤0.01%	1050
2019 Q2	–	Sell	-329	Closed	-$26K	–	607
2019 Q1	$26K	Buy	+329	New	+$24.9K	﹤0.01%	492
2015 Q1	–	Sell	-7,173	Closed	-$238K	–	718
2014 Q4	$238K	Buy	+7,173	New	+$233K	0.03%	323

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Manchester Capital Management's LGND Position: Q2 2026 in Review

Manchester Capital Management held its Ligand Pharmaceuticals (LGND) position steady in Q2 2026 at 9 shares worth $2.85K. The position accounts for ﹤0.01% of the portfolio, ranked #985.

Manchester Capital Management first reported a position in LGND in Q4 2014 and has held it in 5 quarters since. The position peaked at $238K in Q4 2014. 416 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Manchester Capital Management held 9 shares of Ligand Pharmaceuticals worth $2.85K as of Q2 2026.
Manchester Capital Management left its Ligand Pharmaceuticals share count unchanged in Q2 2026.
Ligand Pharmaceuticals made up ﹤0.01% of Manchester Capital Management's portfolio in Q2 2026, its #985 holding.
Manchester Capital Management first reported a position in Ligand Pharmaceuticals in Q4 2014 and has held it in 5 quarters since.
Manchester Capital Management's Ligand Pharmaceuticals position peaked at $238K in Q4 2014.
416 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Manchester Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.